Alzheimer's Research UK is a private limited guarantee non-standard company exemption, registered in England and Wales with registration number 03681291. Established in 1998, it currently maintains an active status. The organization operates from 3 Riverside, Granta Park, Cambridge, CB21 6AD. According to website findings, Alzheimer's Research UK is classified as a charity, focusing on research related to Alzheimer's disease. The company size is currently unknown. It provides research services. The organization’s core focus is on Alzheimer's disease research, a condition that represents the most prevalent cause of dementia globally. The disease is characterized by the accumulation of amyloid plaques and neurofibrillary tangles within the brain, leading to neuronal death and subsequent brain shrinkage. Approximately 6.9 million individuals aged 65 and older in the United States live with Alzheimer’s disease, with over 70% of those affected being 75 years or older. Worldwide, more than 55 million people are affected by dementia. Financial records indicate accounts were filed on March 31, 2025. The company is not subject to charges and is not insolvent. The organization holds a Skilled Worker visa, with a worker (A) rating.

Alzheimer's Research UK is a private limited guarantee non-standard company exemption, registered in England and Wales with registration number 03681291. Established in 1998, it currently maintains an active status. The organization operates from 3 Riverside, Granta Park, Cambridge, CB21 6AD. According to website findings, Alzheimer's Research UK is classified as a charity, focusing on research related to Alzheimer's disease. The company size is currently unknown. It provides research services. The organization’s core focus is on Alzheimer's disease research, a condition that represents the most prevalent cause of dementia globally. The disease is characterized by the accumulation of amyloid plaques and neurofibrillary tangles within the brain, leading to neuronal death and subsequent brain shrinkage. Approximately 6.9 million individuals aged 65 and older in the United States live with Alzheimer’s disease, with over 70% of those affected being 75 years or older. Worldwide, more than 55 million people are affected by dementia. Financial records indicate accounts were filed on March 31, 2025. The company is not subject to charges and is not insolvent. The organization holds a Skilled Worker visa, with a worker (A) rating.